The current paradigm of complement activation after myocardial I/R injury developed from prior work by our lab, among many others, is that ischemia of cardiac cells results in exposure of neo-antigens on the cell surface that can be recognized upon reperfusion by naturally occurring circulating IgM antibodies[77, 78, 103, 104]. The gene discussed is CD40LG; the disease is ischemia.